Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Multiple Myeloma 70Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Mantle-Cell 15Lymphoma, Follicular 15Lymphoma, Large B-Cell, Diffuse 14Leukemia, Myeloid, Acute 14Lymphoma, B-Cell, Marginal Zone 13Lymphoma, Non-Hodgkin 12Recurrence 11Neoplasms, Plasma Cell 10Lymphoma 10Myelodysplastic Syndromes 9Hodgkin Disease 8Neoplasms 7Leukemia 7Burkitt Lymphoma 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, T-Cell, Cutaneous 6Lymphoma, B-Cell 6Sezary Syndrome 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Immunoblastic 4Astrocytoma 4Smoldering Multiple Myeloma 3Prostatic Neoplasms 3Oligodendroglioma 3Melanoma 3

Interventions

ibrutinib 3Rituximab 3Lenalidomide 3spebrutinib 2fludarabine phosphate 2Cyclophosphamide 2tirabrutinib 1ricolinostat 1pembrolizumab 1ofatumumab 1navitoclax 1idelalisib 1fludarabine 1dinaciclib 1blinatumomab 1Rabeprazole 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1KW-2478 1Itraconazole 1Immunotherapy, Adoptive 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Ciclopirox 1Blood Component Removal 1Biological Products 1Bendamustine Hydrochloride 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, B-Cell × Lenalidomide × Clear all
NCT01732861 2019-12-20

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Celgene

Phase 1 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00419250 2019-11-08

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

Celgene

Phase 1 Completed
52 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01400685 2018-01-25

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Massachusetts General Hospital

Phase 1 Completed
34 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡